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Abstract
Objective—There is a paucity of data regarding relations of apolipoproteins (apolipoprotein B
[ApoB] and apolipoprotein A-1 [Apo A-1]), lipoprotein particle measures (low-density lipoprotein
particle concentration [LDLp] and high-density lipoprotein particle concentration [HDLp]), and
lipoprotein cholesterol measures (low-density lipoprotein cholesterol [LDL-C], non–high-density
lipoprotein cholesterol [non– HDL-C], and high-density lipoprotein cholesterol [HDL-C]) with
atherosclerotic plaque burden, plaque eccentricity, and lipid-rich core presence as a marker of
high-risk plaques.
Methods—Carotid artery magnetic resonance imaging was performed in 1,670 Atherosclerosis
Risk in Communities study participants. Vessel wall and lipid cores were measured; normalized
wall index (NWI), standard deviation (SD) of wall thickness (measure of plaque eccentricity) were
calculated; and lipid cores were detected in vessels with ≥1.5 mm thickness. Fasting
concentrations of cholesterol, ApoB and Apo A-1, and LDLp and HDLp were measured.
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Results—Measures of plaque burden (carotid wall volume, wall thickness, and NWI) were
positively associated with atherogenic cholesterol and lipoproteins (p<0.05 for total cholesterol,
LDL-C, non–HDL-C, ApoB, and LDLp), but not with HDL-C, Apo A-1, or HDLp. SD of wall
thickness was associated with total cholesterol (p 0.01) and non-HDL-C (p 0.02). Although
measures of atherogenic or anti-atherogenic cholesterol or lipoprotein were not individually
associated with detection of a lipid-rich core, their ratios (total cholesterol/HDL-C, non–HDL-C/
HDL-C, and LDLp/HDLp) were associated with lipid-rich core presence (p≤0.05).
Conclusion—Extent of carotid atherosclerosis is associated with atherogenic cholesterol and
lipoproteins. Atherogenic/anti-atherogenic cholesterol or particle ratios were associated with
presence of a detectable lipid-rich core.
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Introduction
It has been suggested that measures of low-density lipoprotein (LDL) particles
(Apolipoprotein B [ApoB] or LDL particle number [LDLp] measured by nuclear magnetic
resonance [NMR] spectroscopy) perform better in cardiovascular risk prediction than the
traditional cholesterol measures, LDL cholesterol (LDL-C) and non– high-density
lipoprotein cholesterol (non–HDL-C).1, 2. Though this remains debatable in terms of clinical
outcomes, there is a paucity of data regarding how these measures of particle number or
cholesterol content of the particles relate to measures of either atherosclerotic plaque burden
or presence of lipid-rich necrotic core, one of the features of high risk plaques.3
Atherosclerosis is a dynamic process with a balance between the cholesterol brought into the
intima of the large arteries via atherogenic particles and reverse cholesterol transport
mediated by high-density lipoprotein (HDL) particles.4, 5 Based upon this lipoprotein model
of atherogenesis,4, 5 the use of ratios of atherogenic/anti-atherogenic cholesterol or
lipoprotein measures should provide more information regarding assessment of plaque
burden or lipid-rich core presence compared with the use of these measures individually.
Although carotid intima-media thickness (CIMT) can reliably assess presence or absence of
plaque and provides useful prognostic information,6 magnetic resonance imaging (MRI) of
the carotid arteries extends CIMT measurements to provide useful information regarding
plaque burden, vascular remodeling, and the presence of a detectable lipid-rich necrotic
core.7-10 Similarly, normalized wall index [NWI] (carotid wall area divided by total vessel
area including lumen area) has been used as a measure of plaque burden, and takes into
account inherent differences in wall areas among vessels of different diameters.11-13 In
addition, standard deviation of the wall thickness measurement has been shown to be a
marker of plaque eccentricity.11 Both NWI and standard deviation of the wall thickness have
also been shown to be associated with a prior history of coronary heart disease in a recent
publication.11
Thus the aim of our analysis was to identify which atherogenic or anti-atherogenic
cholesterol or particle parameters can predict the burden of atherosclerosis in the carotid
arteries, plaque eccentricity, and the presence of a detectable lipid-rich core. We also aimed
to identify whether the use of atherogenic/anti-atherogenic cholesterol (or lipoprotein) ratios
can provide information regarding plaque burden and lipid-rich core presence beyond that
provided by the use of atherogenic and antiatherogenic cholesterol (or lipoprotein)
parameters alone.
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Methods for the ARIC MRI study have been described previously.10, 14 Relevant details are
described here. The study sample consisted of members of the Atherosclerosis Risk in
Communities (ARIC) study cohort who participated in the ARIC Carotid MRI substudy in
2004–2005 (Year 18). The ARIC study is a population-based cohort study of cardiovascular
disease incidence among African American and Caucasian adults (n=15,792)15.
The ARIC MRI sampling strategy included approximately 1,200 participants with carotid
artery wall thickness (maximum over 6 sites: left and right of the common, bifurcation,
internal) that was at least >68th percentile as measured by carotid B-mode ultrasound on
ARIC study visits 3 (1993–1995) and 4 (1996–1998). Intima-media thickness (IMT) cut-offs
were 1.35, 1.00, 1.28, and 1.22 mm in Forsyth County, Jackson, Minneapolis, and
Washington County, respectively, representing the 73rd, 69th, 73rd, and 68th percentiles of
maximal IMT. A cohort random sample of approximately 800 participants whose carotid
intima-media thickness was <68th percentile was also included. Ineligibility criteria for the
carotid MRI substudy included standard contra-indications to the MRI exam or to the
contrast agent, carotid revascularization on either side for the low CIMT group or on the
selected side for imaging for the high CIMT group, and difficulties in understanding
questions or in completing the informed consent.
Participant Examination
Protocols for fasting glucose, blood pressure, height and weight measurements were
identical at the baseline ARIC cohort examination and 18 years later at the Carotid MRI
substudy examination. The study was approved by the institutional review committees of all
participating centers, and all participants provided written informed consent.
Traditional cholesterol measurements
Twelve-hour fasting plasma lipid assays were performed on participants of the ARIC MRI
substudy. Plasma samples were collected on ice using EDTA as the anticoagulant at the time
of the MRI visit. Total cholesterol, triglycerides, and HDL-C were measured enzymatically
and expressed in mg/dL units. LDL-C levels were calculated using the Friedewald
equation.16 Non-HDL-C levels were calculated as total cholesterol minus HDL-C. Blind
duplicate coefficient of variation for total cholesterol, HDL-C, and triglycerides were 2.0%,
3.0%, and 2.7%, respectively.
Apolipoprotein measurements
Apolipoproteins (ApoB and Apo A-1) were measured in frozen plasma using a
commercially available immunoturbidimetric assay (OLYMPUS®, Olympus America Inc).
The inter-assay coefficient of variation for Apo A-I and ApoB were 3.9% and 7.2%,
respectively. Intra-assay coefficient of variation for Apo A-1 and ApoB were 1.5% and
1.7%, respectively. Reliability coefficients based on 120 blinded split QC samples were 0.93
and 0.95 for ApoA-I and ApoB, respectively.
Lipoprotein particle analysis
Frozen EDTA plasma samples were thawed, and a 200 μL aliquot withdrawn, refrozen, and
shipped on dry ice to Liposcience, Inc. (Raleigh, NC) for NMR lipoprotein particle analysis.
Using this technique, particle concentrations of lipoproteins of different sizes were
calculated from the measured amplitudes of their spectroscopically distinct lipid-methyl
group.17 The NMR variables examined in this manuscript were total LDL particle
concentration (LDLp) expressed in nmol/L units and total HDL particle concentration
(HDLp) expressed in μmol/L units.
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The methods for acquisition and interpretation of the MRI images collected in the Carotid
MRI substudy have been described previously.10, 14 Briefly, a contrast-enhanced MRI exam
of the thickest 1.6-cm segment of the thicker carotid artery was performed according to a
standard protocol on a 1.5T whole-body scanner as follows: A 3-dimensional time-of-flight
magnetic resonance angiogram (MRA) was acquired through both carotid bifurcations.
Detailed black blood MRI (BBMRI) images were then acquired through the extracranial
carotid bifurcation, known to have a thicker maximum wall by the most recent ultrasound
study, unless the contralateral carotid bifurcation wall appeared to the technologist to be
thicker on the MRA. These BBMRI images consisted of 16 axial T1-weighted, fat-
suppressed slices (thickness=2 mm; acquired in-plane resolution=0.51 × 0.58 mm2; total
longitudinal coverage=3.2 cm) oriented perpendicular to the vessel and centered at the
thickest part of the internal or common carotid artery wall. These 16 slices were acquired 5
minutes after the intravenous injection of gadodiamide (Omniscan, GE Amersham), 0.1
mmol/kg body weight, with a power injector.
Seven readers were trained to interpret the MRI images and contour the wall components
using specialized software (VesselMass, Leiden University Medical Center). Readers were
blinded to the characteristics of the study population. Each reader drew contours to delineate
the lumen, outer wall, lipid core, and calcification. Eight slices centered at the slice with the
thickest wall were analyzed. All exams were assigned quality scores by the reader based on
image quality and protocol adherence; exams that failed were not analyzed.
Using semi-automated software, vessel walls were divided into 12 radial segments, and
mean thickness values were generated for each segment (Figure 1). Standard deviation of
the wall thickness measurement was also computed and provides a measure of the plaque
eccentricity. Area measurements were calculated for the lipid core and calcification
contours. Volumetric data were computed by integrating area measurements over all 8 slices
examined.
Maximum segmental wall thickness (in mm) was defined as the maximum wall thickness of
12 segments at the slice with the largest lipid contour area. Vessel wall area and lumen area
(in cm2) were computed at the slice with the largest mean segmental wall thickness. Volume
measurements for total wall volume (in mm3) was computed by integrating area
measurements over 8 slices. Normalized wall index (NWI) was then calculated. NWI was
derived as carotid wall area divided by the total vessel area. The total vessel area in these
measurements includes the lumen area. Lipid-rich core was represented as a binary variable
(present or absent).
Statistical Methods
All analyses were weighted and appropriately accounted for the stratified random sampling
design of the ARIC Carotid MRI substudy. Analyses were conducted using SAS version 9.1
for descriptive statistics or SUDAAN for domain analysis. Wall thickness and wall volume
were analyzed in the full data set. Due to the resolution constraints of the MRI scan, we
restricted consideration of lipid core to those 1,131 participants whose maximum wall
thickness was ≥1.5 mm. Only 4 lipid cores were excluded using this cut point. Among the
1,131 participants who were included in the analyses, a total of 542 participants had an
identifiable lipid-rich core.
For continuous MRI variables, standardized regression coefficients (β) are presented for
linear regression models, standardizing by one standard deviation (SD) of exposure and
outcome with adjustment for covariates. These β coefficients can be interpreted as number
of SD difference in the dependent variable (e.g., total wall volume) associated with a single
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SD difference in plasma cholesterol or lipoprotein level or their ratio. For the dichotomous
lipid-rich core variable (presence or absence), standardized odds ratio (OR) are presented for
logistic regression models adjusting for covariates. These ORs can be interpreted as the odds
for the presence of lipid-rich core associated with a single SD difference in plasma
cholesterol or lipoprotein level or their ratio. Covariates included for adjustment were age,
race, gender, smoking status, body mass index, blood glucose, hypertensive medication use,
cholesterol-lowering medication use, aspirin use, diabetic medication use, hs-CRP, and
plasma triglyceride concentration. Similarly, the coefficients of determination (R2) were
described for each model including the above-mentioned covariates as well as lipid or
lipoprotein particle measure of interest. R2 can be interpreted as proportion of the variance
in the dependent variable (e.g., total wall volume) as explained by the set of independent
variables in the model including the cholesterol or lipoprotein particle concentration
parameter of interest.
Because the presence of lipid-rich core on carotid MRI has been shown to highly correlate
with carotid wall thickness,10 we conducted additional analyses to examine the presence of
lipid-rich core, while controlling for carotid wall thickness in addition to the covariates
mentioned above.
Results
Final analyses, after excluding those with insufficient quality or missing MRI variables
(n=336) and those missing lipid measurement (n=60) data, included 1,670 participants.
Baseline characteristics and baseline lipid and lipoprotein levels for the current study
participants are shown in Table 1. The mean age of this cohort was 71 years with 49% men
and a predominance of Caucasians (78%). The proportion of participants with history of
diabetes, hypertension, current smoking, or statin medication use was 24%, 68%, 9%, and
39%, respectively. More than half of the patients fulfilled the National Heart, Lung and
Blood Institute/American Heart Association criteria for metabolic syndrome.18 Mean levels
of total cholesterol, LDL-C, non-HDL-C, ApoB and LDLp were 193 mg/dL, 113 mg/dL,
144 mg/dL, 98 mg/dL and 1148 nmol/L, respectively. Mean levels of HDL-C, ApoA-1 and
HDLp were 49 mg/dL, 131 mg/dL, and 35 μmol/L, respectively.
As expected, LDL-C was correlated with ApoB (r=0.74), and LDLp (r=0.66), and non-
HDL-C was even more strongly correlated (r=0.85 for ApoB; r=0.77 for LDLp). HDL-C
levels had a high correlation with Apo A-1 levels (r=0.80), and a more modest correlation
with HDLp (r = 0.63).
Associations between cholesterol or lipoprotein parameters and measures of plaque
burden and plaque eccentricity (Table 2)
Among the atherogenic lipid measures, total cholesterol, LDL-C, non-HDL-C, ApoB, and
LDLp were all associated with maximum wall thickness as well as carotid wall volumes in
fully adjusted models. It can also be noted from Table 2 that the standardized beta
coefficients (β) were numerically higher for total cholesterol (β=0.13), and non-HDL-C
(β=0.13) compared with LDL-C (β=0.09) for total wall volume. The β for total cholesterol
and non–HDL-C were also higher than those obtained for ApoB 0=0.06) and LDLp
(β=0.08).
Anti-atherogenic cholesterol (HDL-C) or lipoprotein parameters (Apo A-1, HDLp) were not
associated with carotid wall volume or maximum wall thickness. Although total cholesterol/
HDL-C ratio and non-HDL-C/ HDL-C ratio were associated with carotid wall volume, they
were not associated with an improvement in model prediction (R2 values) compared with the
use of atherogenic cholesterol or lipoprotein parameters alone.
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Normalized wall index was associated with atherogenic cholesterol (or lipoproteins) and the
ratio of atherogenic/anti-atherogenic cholesterol or lipoproteins, but not when anti-
atherogenic cholesterol or lipoproteins parameters were used alone. Similarly, plaque
eccentricity was positively associated with total cholesterol and non-HDL-C in the fully
adjusted models.
Associations between cholesterol or lipoprotein parameters and presence of lipid-rich
core on carotid MRI (Tables 3 and 4)
Among persons with arteries ≥1.5 mm in thickness, the associations between the presence of
detectable lipid-rich core and various atherogenic or anti-atherogenic lipoprotein cholesterol/
particle measures as well as their ratios on carotid MRI are shown in Table 3. Although
neither atherogenic nor anti-atherogenic lipoprotein measures could individually predict the
presence of lipid-rich core in the plaques, ratios of total cholesterol/ HDL-C, non-HDL-C/
HDL-C, and LDLp/HDLp were associated with the presence of lipid-rich core. Apo B/Apo
A-1 ratio was not significantly associated with presence of lipid-rich core in fully adjusted
models.
Because detection of lipid-rich core is highly dependent on wall thickness,10 we
subsequently added maximum wall thickness to the adjustment model (Table 4). The overall
model prediction (R2) was substantially improved by adding maximum wall thickness to the
model, but the associations between the presence of lipid-rich core and atherogenic/anti-
atherogenic cholesterol as well as lipoprotein ratios were attenuated. On the other hand, the
inverse associations between the presence of lipid-rich core and Apo A-1 (OR=0.84, p=0.08)
or HDLp (OR=0.84, p=0.06) became borderline significant.
Discussion
Our findings indicate that measures of carotid artery plaque burden and plaque eccentricity
were positively associated with atherogenic particle number or atherogenic cholesterol
content (especially total cholesterol and non–HDL-C). Although the various measures of
anti-atherogenic lipids were not associated with measures of plaque burden when examined
individually, the ratio of atherogenic/anti-atherogenic lipids was associated with lipid-rich
core presence in arteries of >1.5 mm thickness. This association between the presence of
lipid-rich core and atherogenic/anti-atherogenic ratios was attenuated once maximum wall
thickness was included in the adjustment model, but the association between anti-
atherogenic lipoprotein measures and the presence of lipid-rich core approached significance
after including maximum wall thickness in the adjustment model. The strengths of
association for carotid plaque burden assessed using total cholesterol and non–HDL-C were
numerically higher compared with LDL-C, ApoB, and LDLp.
Several cholesterol and particle measures of atherogenic lipoproteins have been associated
with measures of plaque burden. In a prior manuscript,19 both small and large LDLp
subclasses were associated with carotid intima media thickness (a marker of carotid plaque
burden). Similarly, LDL-C has been shown to be associated with carotid IMT.20, 21 Our
findings confirm these earlier observations when carotid MRI is used to measure
atherosclerosis burden. We show that all the measures of atherogenic cholesterol or particle
number are indeed associated with measures of plaque burden using carotid MRI.
In addition, two other observations could be made. First, the β coefficients were higher for
total cholesterol and non–HDL-C compared with LDL-C. This is not surprising because
non–HDL-C measures cholesterol content within all the atherogenic particles (very-low-
density lipoproteins, intermediate-density lipoproteins, and lipoprotein(a) in addition to
LDL).22-24 Therefore, non–HDL-C use may provide a more comprehensive assessment of
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the plaque burden. Second, we show that the strength of association (β coefficient) as well as
the overall model prediction (R2) is at least as strong or stronger with measures of
cholesterol content (total cholesterol and non–HDL-C) compared with measures of
atherogenic particle number (ApoB or LDLp).
Presence of lipid-rich core identified by carotid MRI has been shown to have a very strong
association with wall thickness,10 and our models for core which included wall thickness
had substantially larger R2 compared with those without wall thickness. This could be due to
the fact that carotid MRI is not sensitive for detecting very small lipid-rich cores. Individuals
with a higher burden of atherosclerosis (as evidenced by having thicker carotid walls) are
expected to have larger lipid-rich cores. We also showed that after adjusting for maximum
wall thickness which is a measure of the size of the atherosclerotic lesion, the atherogenic
parameters or the ratios of atherogenic/anti-atherogenic parameters were not associated with
lipid-rich core presence. Interestingly, the negative association between HDLp (or Apo A-1)
and presence of lipid-rich core increased after adjustment was made for maximum wall
thickness, and the association became borderline significant. These results indicate that
although atherogenic lipoproteins are the primary determinants of plaque burden, the
development of detectable lipid rich cores in large plaques may be influenced by low levels
of HDL.
Our findings have potentially important research implications in terms of which MRI
parameters to follow when therapies that lower atherogenic lipids or raise anti-atherogenic
lipids are used. Our results indicate that measures of plaque burden could be monitored for
disease progression when evaluating the impact of therapies that lower atherogenic lipids,
whereas lipid-rich necrotic core presence might be an important imaging parameter to
follow with therapies that markedly improve the ratio of atherogenic/anti-atherogenic lipids
by both reducing the atherogenic cholesterol (or lipoproteins) and raising anti-atherogenic
cholesterol (or lipoproteins). Our results showed that although atherogenic lipids can explain
the variance in measures of plaque burden in the artery wall to a greater extent, the
development of plaques with large lipid-rich necrotic cores is more likely to occur when
anti-atherogenic lipid levels are low.
Limitations
The cross-sectional nature of this study does not allow us to imply causal relationships;
however, the findings are valuable for generating hypotheses. We only evaluated the
associations between cholesterol and lipoprotein parameters, and measures of plaque burden
and presence of lipid-rich core. Though there are studies suggesting that wall thickness, wall
area, NWI, and measures of plaque eccentricity can predict cardiovascular outcomes,11 we
did not evaluate cardiovascular outcomes in this cohort given limited statistical power. Our
associations for the presence of lipid-rich core were attenuated once wall thickness was
entered as a covariate in the adjusted models. This observation is not surprising as a prior
study from the ARIC MRI cohort has shown that wall thickness itself is very highly
correlated with the presence of a lipid-rich core.10 Similarly, the resolution constraints of the
MRI limit the ability to fully characterize the presence of lipid-rich core in small plaques.
The strengths of this study include relatively large number of patients in the ARIC MRI
cohort and extensive quality control measures for the carotid MRI as well as lipid and
lipoprotein measurements in the ARIC study. Moreover, representation from both African
American and Caucasian participants makes our results generalizable to a broader
population. To our knowledge, this is the largest study evaluating the associations between
measures of cholesterol content and particle number and carotid plaque characteristics using
carotid MRI as the imaging modality.
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We conclude the measures of plaque burden in the carotid arteries are positively associated
with both cholesterol and particle measures of lipoproteins. Measures of plaque eccentricity
are also positively associated with total cholesterol and non-HDL-C. Although anti-
atherogenic cholesterol or lipoproteins are not directly associated with carotid plaque
burden, the development of detectable lipid rich cores in large plaques could be influenced
by low levels of anti-atherogenic lipoproteins.
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Black blood MRI (BBMRI) slices through the carotid bifurcation and plaque. A long axis
BBMRI image adjacent to the slice shown in Figure 1a was used to orient 8 precontrast
(yellow lines) and 16 postcontrast (yellow and blue lines) slices through the plaque.
Transverse BBMRI image through the thickest part of the plaque (a, broken line) is shown
before (b) and after (c) contrast administration. Contours were drawn on the postcontrast
image to delineate the core (blue), lumen (red) and outer wall (green) (d). The wall was
automatically divided into 12 radial segments and the cap was segmented at 15 ° increments
(e). Segmental thickness measurements were determined by averaging the yellow line
thicknesses for the wall and red line thicknesses for the cap (e).
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Table 1
Baseline characteristics of the study cohort
Characteristics n = 1,670
Age in years, mean ± standard deviation (SD) 71 ± 5.6
Men, n (%) 823 (49.3)
Caucasian, n (%) 1,305 (78.1)
History of diabetes, n (%) 402 (24.3)
History of hypertension, n (%) 1,119 (67.7)
Presence of metabolic syndrome*, n (%) 970 (58)
Current smoking, n (%) 142 (8.6)
Systolic blood pressure (mm Hg), mean ± SD 127 ± 19
Diastolic blood pressure (mm Hg), mean ± SD 66 ± 10.5
Body mass index (kg/m2), mean ± SD 28.3 ± 4.7
hs-CRP mg/L, median (inter-quartile range) 1.97 (1.02-4.02)
Antihypertensive medication use, n (%) 1,140 (68.5)
Antidiabetes medication use, n (%) 253 (15.2)
Statin use, n (%) 639 (38.8)
Aspirin use, n (%) 1,142 (69.3)
Total cholesterol (mg/dL), mean ± SD 193 ± 41
Low-density lipoprotein cholesterol (mg/dL), mean ± SD 113 ±38
Non–high-density lipoprotein cholesterol (mg/dL), mean ± SD 144 ± 37
High-density lipoprotein cholesterol (mg/dL), mean ± SD 49±5
Apolipoprotein B (mg/dL), mean ± SD 98 ±24
Apolipoprotein A-1 (mg/dL), mean ± SD 131 ±18
Low-density lipoprotein particle concentration (nmol/L), mean ± SD 1,148 ±350
High-density lipoprotein particle concentration (μmol/L), mean ± SD 35 ±6
*
Defined by the National Heart, Lung and Blood Institute/American Heart Association criteria18as the presence of 3 or more of the following 5
criteria: waist circumference >40 inches in men and >35 inches in women, triglycerides >150 mg/dL, HDL-C concentration <40 mg/dL in men and
<50 mg/dL in women, blood pressure >130/>85 mm Hg, and fasting glucose >100 mg/dL
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Table 3
Associations between presence of lipid-rich core on the carotid MRI, and cholesterol
content (or lipoprotein) parameters in fully adjusted models*
Presence of lipid-rich core in fully adjusted model
OR** p Model R2†
Atherogenic cholesterol or lipoproteins
Total cholesterol 1.10 0.23 0.12
Low-density lipoprotein cholesterol 1.13 0.14 0.13
Non–high-density lipoprotein cholesterol (non–HDL-C) 1.15 0.08 0.13
Apolipoprotein B (ApoB) 1.08 0.34 0.12
Low-density lipoprotein particle concentration (LDLp) 1.15 0.08 0.13
Anti-atherogenic cholesterol or lipoproteins
High-density lipoprotein cholesterol (HDL-C) 0.91 0.31 0.12
Apolipoprotein A-1 (Apo A-1) 0.90 0.20 0.13
High-density lipoprotein particle concentration (HDLp) 0.88 0.10 0.13
Atherogenic/Anti-atherogenic cholesterol or lipoprotein ratios
Total cholesterol/HDL-C 1.17 0.05 0.13
Non–HDL-C/HDL-C 1.17 0.05 0.13
ApoB/Apo A-1 1.13 0.14 0.13
LDLp/HDLp 1.16 0.04 0.13
*
Adjusted for age, race, gender, smoking status, body mass index, blood glucose, hypertensive medication use, cholesterol-lowering medication
use, aspirin use, diabetic medication use, hs-CRP, and triglycerides
**
* Represent the standardized odds ratios (OR) and can be interpreted as the odds for the presence of lipid-rich core associated with a 1 SD
difference in plasma cholesterol or lipoprotein levels
†
R2 values (coefficient of determination) can be interpreted as proportion of the variance in the dependent variable (e.g. lipid-rich core presence)
as explained by the set of independent variables in the model including the cholesterol or lipoprotein particle parameter of interest
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Table 4
Associations between presence of lipid-rich core on the carotid MRI, and cholesterol content or lipoprotein
parameters in fully adjusted models with additional adjustment for maximum carotid wall thickness*
Presence of lipid-rich core in fully adjusted model plus adjusted for wall
thickness
OR** p Model R2†
Atherogenic cholesterol or lipoproteins
Total cholesterol 0.98 0.85 0.56
Low-density lipoprotein cholesterol 1.02 0.80 0.56
Non–high-density lipoprotein cholesterol (non–HDL-C) 1.04 0.69 0.56
Apolipoprotein B (ApoB) 1.04 0.68 0.56
Low-density lipoprotein particle concentration (LDLp) 1.07 0.44 0.56
Anti-atherogenic cholesterol or lipoproteins
High-density lipoprotein cholesterol (HDL-C) 0.86 0.16 0.56
Apolipoprotein A-1 (Apo A-1) 0.84 0.08 0.56
High-density lipoprotein particle concentration (HDLp) 0.84 0.06 0.56
Atherogenic/Anti-atherogenic cholesterol or lipoprotein ratios
Total cholesterol/HDL-C 1.13 0.20 0.56
Non–HDL-C/HDL-C 1.13 0.20 0.56
ApoB/Apo A-1 1.13 0.20 0.56
LDLp/HDLp 1.14 0.13 0.56
*
Adjusted for covariates as in Table 3 plus maximum carotid wall thickness
**
represent the standardized odds ratios and can be interpreted as the odds for the presence of lipid-rich core associated with a 1 SD difference in
plasma cholesterol or lipoprotein levels
†
R2 values (coefficient of determination) can be interpreted as proportion of the variance in the dependent variable (e.g. lipid-rich core presence)
as explained by the set of independent variables in the model including the cholesterol or lipoprotein particle parameter of interest
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